Phase 1: Patients with aggressive B-cell NHL including, but not limited to, DLBCL and MCL. for Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Massachusetts General Hospital (MGH), Boston, MA
Leukemia+16 More
MB-106 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Eligible Conditions

  • Leukemia
  • Small Lymphocytic Lymphoma, Relapsed
  • Waldenstrom's Macroglobulinemia Refractory
  • Refractory Follicular Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Follicular B-cell Non-Hodgkin's Lymphoma
  • Waldenstrom's Macroglobulinemia Recurrent
  • Refractory Mantle Cell Lymphoma
  • Chronic Lymphoid Leukemia in Relapse

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Leukemia

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: 24 months

24 months
Phase 1: Primary objective
Phase 1: Secondary objective
Phase 2: Primary objective
Phase 2: Secondary objective

Trial Safety

Safety Progress

1 of 3

Other trials for Leukemia

Trial Design

7 Treatment Groups

Phase 1: Patients with aggressive B-cell NHL including, but not limited to, DLBC...
1 of 7
Phase 1: Patients with CLL/small lymphocytic lymphoma (SLL).
1 of 7
Phase 2: Patients with relapsed or refractory DLBCL
1 of 7
Phase 1: Patients with indolent NHL including, but not limited to, FL.
1 of 7
Phase 2: Relapsed or refractory FL
1 of 7
Phase 2: Relapsed or refractory CLL/SLL
1 of 7
Phase 2: Basket - Relapsed or refractory B-cell NHL subtypes
1 of 7
Experimental Treatment

287 Total Participants · 7 Treatment Groups

Primary Treatment: Phase 1: Patients with aggressive B-cell NHL including, but not limited to, DLBCL and MCL. · No Placebo Group · Phase 1 & 2

Phase 1: Patients with aggressive B-cell NHL including, but not limited to, DLBCL and MCL.
Biological
Experimental Group · 1 Intervention: MB-106 · Intervention Types: Biological
Phase 1: Patients with CLL/small lymphocytic lymphoma (SLL).
Biological
Experimental Group · 1 Intervention: MB-106 · Intervention Types: Biological
Phase 2: Patients with relapsed or refractory DLBCL
Biological
Experimental Group · 1 Intervention: MB-106 · Intervention Types: Biological
Phase 1: Patients with indolent NHL including, but not limited to, FL.
Biological
Experimental Group · 1 Intervention: MB-106 · Intervention Types: Biological
Phase 2: Relapsed or refractory FL
Biological
Experimental Group · 1 Intervention: MB-106 · Intervention Types: Biological
Phase 2: Relapsed or refractory CLL/SLL
Biological
Experimental Group · 1 Intervention: MB-106 · Intervention Types: Biological
Phase 2: Basket - Relapsed or refractory B-cell NHL subtypes
Biological
Experimental Group · 1 Intervention: MB-106 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months
Closest Location: Massachusetts General Hospital (MGH) · Boston, MA
Photo of Boston  1Photo of Boston  2Photo of Boston  3
2017First Recorded Clinical Trial
4 TrialsResearching Leukemia
9 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
For patients treated with prior CD19-directed CAR-T therapy, the peripheral blood absolute CD19+ B-cell count, as measured by flow cytometry, has recovered to at least 20 cells/μl.
For patients with CLL, diagnosis of CLL that meets published diagnostic criteria
You have evidence of CD20 expression on the tumor specimen obtained from the original diagnostic biopsy or another tissue biopsy performed prior to enrollment into this study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.